About 40 employees are affected, about 8% of its workforce, according to Pacific Biosciences Of California, Inc.'s latest layoff filing, on August 5, 2026. As of November 15, 2026, Pacific Biosciences Of California, Inc. has reported 4 exit or restructuring plans to the SEC on Form 8-K under Item 2.05. No WARN notice under its name is on file in the states covered here (Form 8-K, August 5, 2026).
10 companies announced layoffs this week, 1 had other signals.
Companies cutting jobs this week. Before you unlock: the company, the number of employees and what is inside. After: every way we found to reach the company. No individual is named in a layoff.
| UPWORK, INC | announced layoffs | |
| PVH CORP. /DE/ | announced layoffs | |
| Battelle | filed a layoff notice for 15 employees | |
| TidalHealth Primary Care | filed a layoff notice for 5 employees | |
| Phunware, Inc. | announced layoffs |
Is this your company?
Owed money by them or selling to them? See the free Snapshot of Pacific Biosciences Of California, Inc.
Free to see. No signup.
People from Pacific Biosciences Of California, Inc. who say they are open to work
Only people who added themselves are listed here. Nobody is named because of a company announcement or a news story, and we have not checked what anyone says about themselves.
Loading the list…
Affected by the Pacific Biosciences Of California, Inc. layoff? Add yourself to the open-to-work list, free
Your entry
Pacific Biosciences Of California, Inc. reported 4 exit or restructuring plans on Form 8-K under Item 2.05, 1 of 4 stating how many employees or positions are affected. Each fact below is the filing's own sentence, quoted and linked. No WARN notice under this company's name is on file in the states covered here.
Did Pacific Biosciences Of California have layoffs in 2026? What its filings say
Pacific Biosciences Of California, Inc. (CIK 1299130) reported 4 exit or restructuring plans to the SEC on Form 8-K under Item 2.05. The sentences below are quoted from the filings as written.
Form 8-K filed 2026-08-05
Employees affected
These restructuring actions are expected to result in a workforce reduction of approximately 40 employees, or approximately 8% of the Company's workforce, as the Company aligns its organizational structure with its strategic priorities.
Expected charges
Including the Reduction in Force and related non-headcount cost actions, the Company expects to reduce its annualized operating expenses by $30 million to $40 million by the end of 2027.
Timing
The Company expects that the Reduction in Force will be completed and that these charges will be incurred in the third quarter of 2026.
Form 8-K filed 2025-04-09
Expected charges
On April 9, 2025, the Company announced a plan to reduce its annualized non-GAAP operating expense run rate costs of approximately $45 million to $50 million.
Form 8-K/A filed 2024-08-07
Locations
At this time, the Company expects to incur charges related to the Expense Reduction Plan to be approximately $27 million in fiscal 2024, consisting primarily of the following: approximately $10 million of compensation and benefits afforded to terminated employees; approximately $12 million associated with the closure of the San Diego office and related costs, including lease related costs; and approximately $4 million of charges for excess inventory due to a decrease in internal demand relating to the expense reduction initiatives.
Timing
The Company expects to recognize substantially all of these charges in the second and third quarter of fiscal 2024.
Form 8-K filed 2024-04-16
Expected charges
On April 16, 2024, the Company announced a plan to reduce its annualized run-rate operating expenses on a non-GAAP basis by $50 million to $75 million by the end of 2024 in relation to the Company's prior guidance of 5% operating expense growth.
Also on the record for Pacific Biosciences Of California, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 9, 2026 | Stake report, Schedule 13G, by THE GOLDMAN SACHS GROUP, INC. | 7.6% of the class | 5%+ stakes | Source |
| November 6, 2026 | Stake report, Schedule 13G, by T. Rowe Price Associates, Inc. | 10.8% of the class | 5%+ stakes | Source |
| November 4, 2026 | Leadership change: Bill Meyer appointed, Chief Accounting Officer | — | Leadership changes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by ARK Investment Management LLC | 9.59% of the class | 5%+ stakes | Source |
| August 5, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| July 9, 2026 | Leadership change: Christopher M. Smith departs, Director | — | Leadership changes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| March 6, 2026 | Leadership change: Michele Farmer departs, Chief Accounting Officer, and 1 more | — | Leadership changes | Source |
| March 5, 2026 | Leadership change: Christopher Gibson appointed, Director, and 1 more | — | Leadership changes | Source |
| February 3, 2026 | Stake report, Schedule 13G/A, by ARK Investment Management LLC | 12.34% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Gregory Boyd Penner | 2.8% of the class | 5%+ stakes | Source |
| November 4, 2025 | Stake report, Schedule 13G/A, by ARK Investment Management LLC | 10.3% of the class | 5%+ stakes | Source |
Keep reading
More on Pacific Biosciences Of California, Inc. and the records around it.
Pacific Biosciences Of California, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Leadership changes Aug 2026
- Who owns it
Companies that share a holder
- EDMOND DE ROTHSCHILD ASSET MANAGEMENT (FRANCE) also filed stake reports on 1 other company: ZipRecruiter, Inc. (Apr 2026)
- ARK Investment Management LLC also filed stake reports on 23 other companies: Beam Therapeutics Inc. (Nov 2026), CERUS CORP (Nov 2026), CRISPR Therapeutics AG (Nov 2026)
- THE GOLDMAN SACHS GROUP, INC. also filed stake reports on 183 other companies: Attovia Therapeutics, Inc. (Nov 2026), OSPREY ACQUISITION CORP. III (Nov 2026), ALLIED GOLD CORPORATION (Nov 2026)
Watch Pacific Biosciences Of California, Inc.
Get an email when Pacific Biosciences Of California, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
What do you want to do with Pacific Biosciences Of California, Inc.?
Want the whole picture on Pacific Biosciences Of California, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Pacific Biosciences Of California, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Pacific Biosciences Of California, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 14 records.
Tools for this story
Each opens in a new tab, filled in for Pacific Biosciences Of California, Inc.. With no account yet, you sign up free and land on the result.
Public companies must also report to the SEC, on Form 8-K under Item 2.05, when they commit to an exit or restructuring plan that will cost them material charges, which is how most large layoffs and closures by listed companies are disclosed. Those filings are national, so they cover companies in every state. Each sentence shown from one is quoted exactly and linked to the filing; where a filing does not state a figure, none is shown.
Where this comes from
Employers covered by the federal WARN Act, and by the stricter laws some states add, must give written notice before a mass layoff or a site closure. The state labor department publishes those notices. Every row here is one of them, taken from that state's own published file and linked to it, so each figure can be checked at the source.
A notice states the employer, the location, the number of employees affected, and when the layoff or closure takes effect. It does not state a reason, and neither does this page. Where a company also appears in SEC filings under the same name and in the same state, its recorded fundraising is shown alongside, as a matter of record rather than as an explanation. New Jersey and Pennsylvania list a notice under the month it was posted or received, not the day, so their notices show a month. Tennessee gives the county rather than the city.
Related
- Intel Corporation: 3,355 jobs, Oct 2026 layoff notice within 90 days (2026-10-22)
- Avidity Biosciences, Inc.: 40 jobs, Oct 2026 layoff notice within 90 days (2026-10-29)
- Dreyer's Grand Ice Cream: 3,304 jobs, Oct 2026 layoff notice within 90 days (2026-10-20)
- Dropbox, Inc.: 2 SEC filings, Oct 2026 layoff notice within 90 days (2026-10-28)
- Crinetics Pharmaceuticals, Inc.: 78 jobs, Nov 2026 layoff notice within 90 days (2026-11-03)
- Peraton: 379 jobs, Oct 2026 layoff notice within 90 days (2026-10-16)
Who owns Pacific Biosciences of California, Inc.? Owners, funding and legal record
Cite this page
https://mentionfox.com/layoffs/pacific-biosciences-of-california